Call Extraction: MedScout Training — East Area

DDX ID: 1133 Date: 2025-11-20 Duration: ~52 minutes Participants: Phil Cranmer, Cole Landowski, Dale Lindsay (East area, northern territory), Sam Wilson, Carmen Rocco III, Doug Kissell (absent — client lunch) — CDL. Kathryn White (departing for maternity leave), Meaghan DePeter (taking over) — MedScout. Call type: Initial platform training and onboarding for East area sales team. Phil co-led based on his pilot experience. Triage: Very rich. Dale’s field perspective calibrates targeting thresholds, IDN filtering needs, and data accuracy expectations against ground truth from actual prospecting.

Distinct Insights

1. The real SPECT threshold is 800/year (70/month minimum), not 200 — field-calibrated

What: Dale Lindsay: “I usually 800 a year is 70 a month, which is on the, that would be the low end.” And: “Anybody with 130 to 150 a month would be a good target for us.” The platform’s built-in 200/year threshold was too low to be useful — Dale would start at 1,000+/year and work down.

So what: This threshold comes up across multiple calls, and different people mean different things by it.

Phil (Oct 2025, call 0686 and earlier): Used 200 as the floor in the platform’s pre-built targeting strategy. His framing: “The 200 is just, you can’t go lower than that, but it’s going to return you the results going from highest to lowest, you’re just not going to see anything below 200.” Phil’s 200 answers the question: “is there meaningful nuclear cardiology activity here?” Below 200 SPECT/year, a facility isn’t doing enough cardiac imaging to even consider.

Dale (this call, Nov 2025): Challenged 200 as too low for actual field targeting. “200 a year is a little light because that’s about 18 a month.” His field-calibrated minimum is 800/year (70/month). His sweet spot is 130-150/month (1,560-1,800/year). Dale’s 800 answers a different question: “would this practice support a CDL equipment placement?” At 200/year (~18/month), a practice doesn’t generate enough scan volume for CDL’s lease economics to work. At 800/year, it starts making sense — and since claims underreport by 50-100%, a practice showing 800 in data might actually be doing 1,200-1,600.

Dale’s methodology: Start at the top of the volume-sorted list and work down: “I’m going to go down through that list and I’m going to start with obviously people that are doing accounts that are doing a 1,000 plus a year… that’s kind of my low.” Set the data floor low enough to avoid missing anyone, then use field judgment to decide where the cutoff should be for each territory. Better to review extra prospects than miss a high-volume practice that’s underreported in claims data.

The reconciliation: Phil’s 200 is a data engineering floor — keep noise out of the platform. Dale’s 800 is a field qualification floor — below this, don’t spend time visiting. The CDL fingerprint spec v3.1 uses 200, which reflects Phil’s data floor but understates the operational reality. The 2025-05-05 orientation session flagged this: the real targeting threshold is 800+/year.

Speaker credibility: Dale is an experienced BDM with direct field knowledge. Very high on targeting thresholds — this is his daily work. Scope: Private practice targeting specifically. Hospital thresholds may differ — the health system team (Lynette, Todd) uses system-wide portfolio analysis where the economics are evaluated differently. Motion: Private practice team (BDMs).

2. Claims data underreports by 50-100% — confirmed with a specific example

What: Dale: “I just went and did a lunch the other day out on Cape Cod and our previous data set showed that this place did 800 SPECTs a year, which is about 70 a month. And when we get in there, they actually did more like 150 a month twice as much.”

So what: This Cape Cod example provides field validation of the 50-100% underreporting. The practice showed 800/year in data but was actually doing ~1,800/year. Dale’s takeaway is practical: “I look at this data as important for just mining and again getting us directionally correct, so we can go out and prospect and find new clients.” Claims data is a directional screening tool, not ground truth. The team sets thresholds low enough that even with 100% underestimation, qualified prospects still appear in results. This is how CDL calibrates their targeting methodology against known data limitations.

Speaker credibility: Direct field verification. Very high — this is observed, not estimated. Scope: Likely generalizable across markets. Commercial claims may underreport more or less than Medicare depending on payer coverage in a given market. Motion: Both motions — affects all claims-based targeting.

3. Private practice vs. hospital is a deal-killing distinction, not a preference

What: Dale: “What I’m looking for is private practice, people — doctors that are not employed physicians… if I know that a physician is not employed and they own their practice, that’s really who I’m going after.” And: “If I walk in there and there’s 15 docs, they got a ton of SPECT, no PET, but they say, oh, we’re part of MedStar, we’re part of Ascension or we’re part of Trinity, then we’re kind of — we’re going to be at a standstill. It doesn’t mean we can’t offer them a cardiac. That solution is just — that’s a way different animal than what we’re going after.”

So what: For the private practice BDM team, hospital/health system affiliation doesn’t just change the approach — it kills the deal. Health system contracting processes stall or eliminate deals regardless of clinical fit. This is structural: hospital-employed physicians can’t make autonomous purchasing decisions. The BDM motion is exclusively physician-owned practices. IDN contamination in targeting results wastes expensive field time. Dale named specific health systems that appeared in his results: Inova, Atlanticare, MedStar, Monmouth (already engaged with competitor).

Speaker credibility: Dale, experienced BDM. Very high — this is operational reality, not strategy. Scope: Private practice BDM team universally. The hospital team (Lynette, Todd) has its own separate approach for health systems. Motion: Private practice team.

4. Private equity-owned practices are targets, not exclusions — but require different preparation

What: Dale raised PE ownership as something he wants to see. Phil clarified: “Private equity owns private practice, cardiology… groups. They’re still targets. I think what Dale wants to filter out is hospitals slash IDNs. And then if it is a private practice and it is owned by private equity, is there a way to know that?”

So what: PE-backed cardiology groups remain valid targets because they operate with autonomous purchasing decisions — unlike hospital-employed physicians. But knowing about PE ownership matters for preparation: PE-backed practices may have different capital approval processes, growth mandates, or decision timelines than independently physician-owned practices. Dale wants the data not to exclude but to prepare. This is a nuance the targeting needs to capture: physician-owned, PE-backed, and hospital-affiliated are three different categories with different commercial implications, not a binary employed/independent split.

Speaker credibility: Dale (field) + Phil (confirming). High. Scope: Private practice motion. Motion: Private practice team.

5. CDL’s core business model stated plainly — targeting criteria for private practice

What: From the meeting context: “CDL Nuclear targets private practice cardiologists currently performing SPECT imaging (minimum ~800 studies annually, 70/month) who haven’t adopted cardiac PET technology. Hospital-employed physicians and health system-owned practices create contracting roadblocks that stall deals, so the team focuses exclusively on physician-owned practices. After equipment placement, they need precise data to identify referral networks and help clients grow procedure volume.”

So what: This is the most concise statement of CDL’s private practice business model across all documents. Three components: (1) find physician-owned practices doing high-volume SPECT with no PET, (2) place equipment, (3) grow procedure volume through referral network development. The post-sale piece is as important as the targeting — CDL’s relationship doesn’t end at equipment placement. They need ongoing data to help clients grow, which is Cole’s daily work (the BDM support and PCP referral program from the anchor notes).

Speaker credibility: Stated as company description, confirmed by multiple team members throughout the call. Scope: Private practice motion comprehensively. Motion: Private practice team.

6. Phil co-led the training — internal champion enabling adoption

What: Phil participated in the MedScout pilot and co-led the East area training. Kathryn: “Phil, I have not had anybody else co-lead a kickoff in this manner before.” Phil: “I had a good teacher, Catherine.”

So what: Phil isn’t just CDL’s strategist — he’s MedScout’s internal champion. He learned the platform during the pilot and now teaches his own team. This accelerates adoption because reps hear from a colleague who understands their workflow, not an outside vendor. It also means Phil has shaped the platform configuration to CDL’s needs (pre-built strategies, code groupings, territory setup). This is operationally significant: if Phil leaves or disengages, CDL’s platform adoption could stall. Doug (absent, but “knows this just as good as anybody”) is a second internal champion.

Speaker credibility: Observed behavior, not claimed. Scope: Company-wide — Phil’s role applies across all motions. Motion: Both.

7. Six pre-built targeting strategies — CDL’s operational taxonomy

What: Phil walked through six pre-configured strategies:

All sites, high volume SPECT, inbound referral pathways
All sites, high volume cardiac PET (78431 + 78492)
All sites, high volume oncology PET
All sites, billing SPECT but no cardiac PET (primary targeting)
Private practice only, billing 200+ SPECT but no cardiac PET (refined targeting)
[Not detailed]

Doug shaped Strategy 4 vs. 5: he wanted to see hospital physicians doing SPECT-no-PET alongside private practices because hospital physicians “may be going out into private practice” — future opportunities.

So what: The strategy taxonomy reveals how CDL thinks about their market. Strategy 2 (high cardiac PET volume) identifies existing competitors or customers. Strategy 3 (oncology PET) identifies infrastructure — facilities with PET cameras potentially available for cardiac use. Strategy 4 vs. 5 reveals a tension between pure private practice targeting and market intelligence gathering. Doug’s reasoning is significant: a hospital-employed cardiologist doing high-volume SPECT who goes into private practice becomes an immediate target. CDL wants to see those physicians now even if they can’t sell to them yet.

Speaker credibility: Phil (platform architect) and Doug (field-informed refinement). High. Scope: Company-wide platform configuration. Motion: Both — strategies serve both motions differently.

8. Treating vs. referring provider distinction matters for post-sale strategy

What: Dale confused by referral data: “These doctors… they’ll refer it’s… SPECT, right?” Kathryn clarified the treating vs. referring toggle. Dale then asked the deeper question: are referring physicians ordering specific procedures (SPECT), or just referring patients for the cardiologist to decide?

So what: This distinction determines CDL’s post-sale business development strategy. If referring PCPs are ordering SPECT specifically, those PCPs control the imaging modality decision — making them targets for PET education (“did you know PET is now the preferred test?”). If PCPs just refer patients and the cardiologist decides imaging, the education target is the treating cardiologist. This connects directly to Cole’s PCP referral program from the anchor notes. The claims data can show which model operates at each practice — but the team needs to understand what the referral attribution actually means.

Speaker credibility: Dale asking the question, Kathryn answering. The question itself reveals field sophistication about referral dynamics. Scope: Post-sale, private practice motion primarily. Motion: Private practice team (post-sale).

9. MedScout tells CDL WHO to contact; ZoomInfo tells them HOW

What: Kathryn was transparent: “We do not purport ourselves to be an email provider… We do our best to scrape it from the internet, but this is not where we primarily focus our efforts.” Phil redirected: “Dale, keep in mind, Cole has a subscription to ZoomInfo and that is damn accurate.”

So what: CDL uses a two-tool model: MedScout for claims intelligence and provider identification (who matters and why), ZoomInfo for verified contact data (email, phone). This division of labor is deliberate, not a limitation. The fingerprint insight is that CDL’s workflow requires both capabilities — neither tool alone solves their problem. MedScout without contact data identifies the right people but can’t reach them. ZoomInfo without claims data can reach people but can’t identify the right ones.

Speaker credibility: Phil (operational direction) and Kathryn (honest product limitation). High. Scope: Company-wide. Motion: Both.

Transcription Notes

“Catherine White” in transcript is Kathryn White (MedScout). Phil calls her “Catherine” once, likely a familiarity/nickname.
“Megan” is Meaghan DePeter (MedScout, taking over from Kathryn).
“Doug” is Doug Kissell (absent, participated in pilot).
“Carmen Rocco” — full name Carmen Rocco III (email: carmenroccoiii@cdlnuclear.com).
The transcript refers to MedScout’s previous competitor as “Acuity” — this is AcuityMD.